Nabriva Therapeutics plc (NASDAQ:NBRV) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,540,000 shares, a decrease of 31.3% from the August 15th total of 2,240,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.2% of the company’s stock are short sold.
NBRV has been the topic of a number of recent analyst reports. HC Wainwright restated a “neutral” rating on shares of Nabriva Therapeutics in a research note on Wednesday, May 26th. Zacks Investment Research cut shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 4th.
In other news, CEO Theodore R. Schroeder acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 14th. The shares were bought at an average cost of $1.13 per share, with a total value of $56,500.00. Following the transaction, the chief executive officer now owns 226,875 shares of the company’s stock, valued at approximately $256,368.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.93% of the company’s stock.
Shares of NBRV stock traded down $0.03 on Monday, hitting $1.12. The stock had a trading volume of 661,163 shares, compared to its average volume of 2,441,376. The company has a market cap of $557.08 million, a PE ratio of -1.12 and a beta of 1.84. The company has a quick ratio of 4.40, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The business has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.39. Nabriva Therapeutics has a one year low of $1.00 and a one year high of $6.19.
Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.06. Nabriva Therapeutics had a negative net margin of 210.82% and a negative return on equity of 63.27%. The firm had revenue of $8.24 million for the quarter, compared to the consensus estimate of $5.99 million. Equities research analysts expect that Nabriva Therapeutics will post -1.18 EPS for the current year.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.